Want to see HK:6855 full AI Analyst Report?
6855 Stock Chart & Stats
HK$50.90
-HK$0.65(-1.60%)
At close: 4:00 PM EST
HK$50.90
-HK$0.65(-1.60%)
Day’s Range― - ―
52-Week RangeHK$30.00 - HK$95.35
Previous CloseN/A
Volume1.20M
Average Volume (3M)2.29M
Market Cap
HK$13.51B
Enterprise ValueHK$18.83K
Total Cash (Recent Filing)HK$2.47B
Total Debt (Recent Filing)HK$1.98B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Aug 19, 2026EPS Estimate
-0.6Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.46
Shares Outstanding373,611,240
10 Day Avg. Volume1,948,642
30 Day Avg. Volume2,293,783
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.61
Price to Sales (P/S)29.89
P/FCF Ratio-13.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$51.41Price Target Upside1.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-1.47
Revenue Forecast (FY)HK$840.82M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained high revenue growth (~43% in 2025) signals accelerating commercial traction or successful advancement of pipeline assets. Over a multi-month horizon this underpins scaling opportunities, supports R&D reinvestment, and validates market demand for core oncology-focused products.
High Gross MarginsVery high gross margins (mid-70%+ in 2025, ~97% in 2024) indicate a premium, asset-light product profile typical of successful biotech therapeutics. Durable margin strength provides operating leverage as sales scale and allows a larger share of revenue to fund R&D and commercialization.
Improved LeverageMeaningful reduction in leverage (debt-to-equity ~1.5x in 2025 vs much higher prior ratios) improves solvency and reduces refinancing risk. Over 2–6 months this enhances financial flexibility to fund trials or launches without immediate distress-driven dilution.
Bears Say
Deep Operating LossesExtremely negative net margin (~-216%) and large operating losses reflect an income statement structurally far from breakeven. Persisting losses depress retained earnings and require continuous funding, limiting the company's ability to self-finance growth or withstand adverse clinical outcomes.
Intensified Cash BurnOperating cash flow and free cash flow deteriorated sharply (OCF ≈ -1.17B; FCF ≈ -1.20B), indicating heavier near-term cash needs. This structurally increases reliance on external funding, raising dilution risk and potentially constraining R&D or commercialization timelines if capital access tightens.
Negative Return On EquityA deeply negative ROE (~-91%) signals that existing equity capital is being eroded rather than creating shareholder value. Over months this heightens the probability of additional equity raises or restructurings, which can dilute existing holders and reflect persistent profitability challenges.
Ascentage Pharma Group International News
6855 FAQ
What was Ascentage Pharma Group International’s price range in the past 12 months?
Ascentage Pharma Group International lowest stock price was HK$30.00 and its highest was HK$95.35 in the past 12 months.
What is Ascentage Pharma Group International’s market cap?
Ascentage Pharma Group International’s market cap is HK$13.51B.
When is Ascentage Pharma Group International’s upcoming earnings report date?
Ascentage Pharma Group International’s upcoming earnings report date is Aug 19, 2026 which is in 8 days.
How were Ascentage Pharma Group International’s earnings last quarter?
Ascentage Pharma Group International released its earnings results on Mar 25, 2026. The company reported -HK$2.085 earnings per share for the quarter, missing the consensus estimate of -HK$0.815 by -HK$1.27.
Is Ascentage Pharma Group International overvalued?
According to Wall Street analysts Ascentage Pharma Group International’s price is currently Undervalued.
Does Ascentage Pharma Group International pay dividends?
Ascentage Pharma Group International does not currently pay dividends.
What is Ascentage Pharma Group International’s EPS estimate?
Ascentage Pharma Group International’s EPS estimate is -0.6.
How many shares outstanding does Ascentage Pharma Group International have?
Ascentage Pharma Group International has 373,611,240 shares outstanding.
What happened to Ascentage Pharma Group International’s price movement after its last earnings report?
Ascentage Pharma Group International reported an EPS of -HK$2.085 in its last earnings report, missing expectations of -HK$0.815. Following the earnings report the stock price went down -3.126%.
Which hedge fund is a major shareholder of Ascentage Pharma Group International?
Currently, no hedge funds are holding shares in HK:6855
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ascentage Pharma Group International Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$51.41 (1.00% Upside)
HK$51.41 (1.00% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
46.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
58.57%
Trailing 12-Months
Company Description
Ascentage Pharma Group International
Ascentage Pharma Group International is a clinical-stage biopharmaceutical firm dedicated to discovering and developing innovative therapies for various cancers, chronic hepatitis B virus (HBV), and age-related conditions. Its operations are concentrated across the United States and Mainland China. Ascentage Pharma's flagship therapeutic candidate, HQP1351 (Olverembatinib), is a BCR-ABL inhibitor specifically designed to target BCR-ABL mutants, including those carrying the T315I mutation. This compound is intended for patients suffering from chronic phase chronic myeloid leukemia that has become resistant to tyrosine kinase inhibitors. Beyond HQP1351, the company boasts a robust pipeline. This includes APG-2575 (Pelcitoclax), an orally administered, selective Bcl-2 inhibitor undergoing Phase Ib/II clinical studies for hematologic and solid tumors; APG-115 (Alrizomadlin), an oral small molecule designed to inhibit the MDM2-p53 protein-protein interaction for various solid and hematological malignancies; and APG-1387 (Nevadotinib), a small molecule inhibitor of apoptosis proteins targeting advanced solid tumors and chronic HBV infections. Further advancing its portfolio, Ascentage is developing APG-1252 (Atoloclab), a small molecule drug aimed at restoring apoptosis by selectively inhibiting Bcl-2 and Bcl-xL proteins for conditions such as small cell lung cancer (SCLC), lymphoma, and other solid tumors. The pipeline also features APG-2449 (Glecirasib) for non-small-cell lung carcinoma (NSCLC); APG-5918, an orally available and selective EED inhibitor with best-in-class potential in its preclinical phase; APG-265, currently in IND-enabling stages for hematological and solid tumors; and UBX1967/1325, a Phase II candidate targeting the Bcl family for diabetic macular edema (DME). The company maintains strategic collaboration agreements with prominent biotechnology and pharmaceutical companies, as well as academic institutions. Key partners include Innovent Biologics, Inc., the National Cancer Institute, Pfizer Inc., and Clover Biopharmaceuticals (Hong Kong) Co., Limited. Established in 2009, Ascentage Pharma is headquartered in Suzhou, China.
6855 Stock 12 Month Forecast
Average Price Target
HK$51.41
▲(1.00% Upside)
Technical Analysis
Zai Lab Ltd
―
InnoCare Pharma Ltd.
―
Everest Medicines Ltd.
―
CARsgen Therapeutics Holdings Ltd.
―
CStone Pharmaceuticals
―